Banque Cantonale Vaudoise Acquires 3,247 Shares of IDEXX Laboratories, Inc. $IDXX

Banque Cantonale Vaudoise raised its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 54.4% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 9,213 shares of the company’s stock after acquiring an additional 3,247 shares during the quarter. Banque Cantonale Vaudoise’s holdings in IDEXX Laboratories were worth $5,177,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Assenagon Asset Management S.A. boosted its holdings in shares of IDEXX Laboratories by 13.5% in the 1st quarter. Assenagon Asset Management S.A. now owns 85,835 shares of the company’s stock valued at $48,230,000 after buying an additional 10,226 shares in the last quarter. Andina Capital Management LLC acquired a new position in IDEXX Laboratories during the 1st quarter valued at about $310,000. SVB Wealth LLC raised its stake in IDEXX Laboratories by 17.4% in the first quarter. SVB Wealth LLC now owns 7,335 shares of the company’s stock valued at $4,121,000 after buying an additional 1,089 shares during the last quarter. Atlas Brown Inc. raised its stake in IDEXX Laboratories by 20.1% in the first quarter. Atlas Brown Inc. now owns 1,071 shares of the company’s stock valued at $602,000 after buying an additional 179 shares during the last quarter. Finally, PKO Investment Management Joint Stock Co boosted its holdings in IDEXX Laboratories by 6.5% in the first quarter. PKO Investment Management Joint Stock Co now owns 3,300 shares of the company’s stock worth $1,854,000 after acquiring an additional 200 shares in the last quarter. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

IDEXX Laboratories Trading Up 1.5%

NASDAQ IDXX opened at $549.16 on Thursday. IDEXX Laboratories, Inc. has a 1 year low of $506.91 and a 1 year high of $769.98. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.12 and a quick ratio of 0.82. The company has a market capitalization of $43.32 billion, a PE ratio of 40.44, a P/E/G ratio of 2.96 and a beta of 1.55. The company has a fifty day moving average of $559.95 and a 200 day moving average of $616.34.

IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Tuesday, May 5th. The company reported $3.47 EPS for the quarter, topping the consensus estimate of $3.41 by $0.06. The firm had revenue of $1.14 billion for the quarter, compared to analyst estimates of $1.12 billion. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.IDEXX Laboratories’s revenue for the quarter was up 14.3% compared to the same quarter last year. During the same period last year, the company earned $2.91 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Research analysts forecast that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on IDXX. Stifel Nicolaus dropped their price target on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a research note on Tuesday, March 31st. Citigroup assumed coverage on shares of IDEXX Laboratories in a research note on Wednesday, April 15th. They set a “neutral” rating and a $650.00 price target on the stock. UBS Group decreased their price target on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a report on Tuesday, April 28th. Weiss Ratings downgraded shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research note on Monday, May 11th. Finally, Wall Street Zen raised shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Saturday, June 13th. Seven investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $751.00.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.